PDF《长春达兴药业股份有限公司》

C

1 C * For identification purposes only The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

长春达兴药业股份有限公司CHANGCHUN DA XING PHARMACEUTICAL COMPANY LIMITED* (a joint stock limited company incorporated in the People's Republic of China) (Stock Code: 8067) CHANGE OF ADDRESS C PRINCIPAL PLACE OF BUSINESS IN HONG KONG, APPOINTMENT OF CHIEF EXECUTIVE OFFICER, APPOINTMENT OF COMPANY SECRETARY, QUALIFIED ACCOUNTANT AND CHANGE OF AUTHORIZED REPRESENTATIVE The Board hereby announces that the address of the principal place of business in Hong Kong will be changed to Room 903, 9/F, Far East Consortium Building,

121 Des Voeux Road Central, Hong Kong with effect from

1 February 2006. Mr. Li Gang was appointed as the chief executive officer with effect from

12 January 2006. Mr. Zhang Dong Hai resigned from the office of authorized representative with effect from

24 January 2006. Mr. Wong Siu Kui was appointed as the company secretary, the qualified accountant and the authorized representative with effect from

24 January 2006. Trading in shares of the Company was suspended effective from

28 July

2005 and remains suspended until further notice. The board of directors ("the Board") of Changchun Da Xing Pharmaceutical Company Limited (the "Company") announces that the address of the principal place of business of the Company in Hong Kong will be changed to Room 903, 9/F, Far East Consortium Building,

121 Des Voeux Road Central, Hong Kong with effect from

1 February 2006. The Board is pleased to announce that Mr. Li Gang ("Mr. Li") has been appointed as the chief executive officer with effect from

12 January 2006. Mr. Li aged 45, graduate in the People Republic of China. Mr. Li had been the Chairman of Paramount (Hong Kong) Pharmacy International Holdings Limited from

1998 to

2005 and the Chairman of Jilin Province Weichuang Technology Development Limited* from

2003 to 2005. He has over

8 years experience in the senior management position of the pharmaceutical industry. C

2 C The Board further announces that Mr. Zhang Dong Hai ("Mr. Zhang") has resigned as the authorized representative with effect from

24 January

2006 and he is continuing to take the position of executive director of the Company. The Board announces that, in compliance with rules 5.14 and 5.15 of the GEM Listing Rules, Mr. Wong Siu Kui ("Mr. Wong") has been appointed as the company secretary, the qualified accountant and the authorized representative of the Company with effect from

24 January 2006. Mr. Wong holds a Bachelor degree of Commerce, major in accounting and finance from the University of Melbourne, Australia. Mr. Wong has over

5 years experience in accounting and auditing and he is an associate member of Hong Kong Institute of Certified Public Accountants and CPA Australia. The Board would like to take this opportunity to welcome Mr. Li and Mr. Wong to the Company. Trading in shares of the Company was suspended effective from

28 July

2005 and remains suspended until further notice. By order of the Board Changchun Da Xing Pharmaceutical Company Limited Qu Lian Qin Chairman Changchun, the PRC,

24 January,

2006 As at the date of this announcement the Board comprises five executive directors, being Qu Lian Qin, Yu Cheng Kun, Lu De Yi, Guo Bin and Zhang Dong Hai;